CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.45B, above the global median of $1.18B
- PositionProfit margin is 324.9%, higher than 95% of its Biotechnology peers (median -32.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
1.45BUSDvs all stocks (USD)
Trailing P/E
12.17xvs Biotechnology peers
Revenue (TTM)
38.42MUSDvs all stocks (USD)
Profit Margin
324.88%vs Biotechnology peers
Beta
2.60xvs all stocks
52-Week Change
380.38%vs all stocks
Market Capitalization
1.45BUSDvs all stocks (USD)
Enterprise Value
1.62BUSDvs all stocks (USD)
Trailing P/E
12.17xvs Biotechnology peers
Forward P/E
16.33xvs Biotechnology peers
PEG Ratio
-0.0858xvs Biotechnology peers
Price to Sales (TTM)
37.83xvs Biotechnology peers
Enterprise to Revenue
42.12xvs Biotechnology peers
Enterprise to EBITDA
-22.51xvs Biotechnology peers
Gross Margin
97.20%vs Biotechnology peers
Profit Margin
324.88%vs Biotechnology peers
Operating Margin
0.26%vs Biotechnology peers
Return on Assets (TTM)
-18.68%vs Biotechnology peers
Revenue (TTM)
38.42MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5460USDUpdated Sep 28, 2026Quarterly Revenue Growth
188.38%vs Biotechnology peers
Gross Profit (TTM)
14.73MUSDvs all stocks (USD)
EBITDA (TTM)
-71.91MUSDvs all stocks (USD)
Net Income (TTM)
116.53MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-68.67MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-122.80MUSDvs all stocks (USD)
Pre-tax Income
-2.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.01MUSDFY2025 · Dec 31, 2025Net Income
-3.35MUSDFY2025 · Dec 31, 2025EBIT
-122.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-236.78MUSDFY2025 · Dec 31, 2025Research & Development
81.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.06MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.0500USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.0500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
63.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
63.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-3.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-877.00KUSDFY2025 · Dec 31, 2025Free Cash Flow
-240.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
9.66MUSDFY2025 · Dec 31, 2025Income Tax Paid
153.00KUSDFY2025 · Dec 31, 2025Interest Paid
35.42MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-3.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
964.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.19MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-37.13MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
30.45MUSDFY2025 · Dec 31, 2025Capital Expenditures
239.94MUSDFY2025 · Dec 31, 2025Purchase of Investments
-185.31MUSDFY2025 · Dec 31, 2025Sale of Investments
109.90MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
164.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-89.16MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
-49.82MUSDFY2025 · Dec 31, 2025Shares Outstanding
72.09MSharesUpdated Sep 28, 2026Float Shares
69.29MSharesUpdated Sep 28, 2026Shares Short
12.49MSharesUpdated Sep 28, 2026Short Ratio
7.92daysvs all stocks
Short % of Shares Outstanding
17.89%vs all stocks
% Held by Insiders
4.08%vs all stocks
% Held by Institutions
50.94%vs all stocks
Total Cash (MRQ)
131.95MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.82USDUpdated Sep 28, 2026Total Debt (MRQ)
296.87MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.95xvs Biotechnology peers
Book Value per Share (MRQ)
-0.7120USDUpdated Sep 28, 2026Total Assets
325.63MUSDvs all stocks (USD)
Total Current Assets
215.67MUSDFY2025 · Dec 31, 2025Total Liabilities
446.86MUSDFY2025 · Dec 31, 2025Total Non-current Assets
109.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
368.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
78.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
9.66MUSDFY2025 · Dec 31, 2025Other Short-term Investments
162.14MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.44MUSDFY2025 · Dec 31, 2025Accounts Payable
4.76MUSDFY2025 · Dec 31, 2025Short-term Debt
23.36MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.47MUSDFY2025 · Dec 31, 2025Other Current Liabilities
20.55MUSDFY2025 · Dec 31, 2025Long-term Debt
215.78MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
147.32MUSDFY2025 · Dec 31, 2025Common Stock (Book)
716.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-913.70MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-121.23MUSDvs all stocks (USD)
52-Week Low
4.06USDUpdated Sep 28, 202652-Week High
21.24USDUpdated Sep 28, 202652-Week Change
380.38%vs all stocks
Beta
2.60xvs all stocks
50-Day MA
16.02USDUpdated Sep 28, 2026200-Day MA
12.78USDUpdated Sep 28, 2026Avg 10-Day Volume
1.84MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.73MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
1.65USDUpdated Sep 28, 2026Other Income / Expense
114.94MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 324.9%, higher than 95% of its Biotechnology peers (median -32.5%)Significant
Profit margin: 3.25Industry median: -0.32Industry P95: 0.39Peers compared: 193
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 116,533,000Operating Cash Flow (USD, TTM): -68,672,000
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.45B, above the global median of $1.18BNotable
Market cap (USD): 1,453,557,385Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule